4.5 Article

The Ohio Patient Navigation Research Program: Does the American Cancer Society Patient Navigation Model Improve Time to Resolution in Patients with Abnormal Screening Tests?

期刊

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 21, 期 10, 页码 1620-1628

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-12-0523

关键词

-

资金

  1. Special Initiative Research Scholar Grant from the American Cancer Society [112190-SIRSG-05-253-01]
  2. National Cancer Institute Center to Reduce Health Disparities [P30CA016058]
  3. American Cancer Society
  4. National Cancer Institute
  5. National Center for Research Resources [UL1RR025755, KL2RR025754, TL1RR025753]
  6. National Center for Advancing Translational Sciences [8KL2TR000112-05, 8UL1TR000090-05, 8TL1TR000091-05]

向作者/读者索取更多资源

Background: Patient navigation (PN) has been suggested as a way to reduce cancer health disparities; however, many models of PN exist and most have not been carefully evaluated. The goal of this study was to test the Ohio American Cancer Society model of PNas it relates to reducing time to diagnostic resolution among persons with abnormal breast, cervical, or colorectal cancer screening tests or symptoms. Methods: A total of 862 patients from 18 clinics participated in this group-randomized trial. Chart review documented the date of the abnormality and the date of resolution. The primary analysis used shared frailty models to test for the effect of PN on time to resolution. Crude HR were reported as there was no evidence of confounding. Results: HRs became significant at 6 months; conditional on the random clinic effect, the resolution rate at 15 months was 65% higher in the PN arm (P = 0.012 for difference in resolution rate across arms; P = 0.009 for an increase in the HR over time). Conclusions: Participants with abnormal cancer screening tests or symptoms resolved faster if assigned to PN compared with those not assigned to PN. The effect of PN became apparent beginning six months after detection of the abnormality. Impact: PN may help address health disparities by reducing time to resolution after an abnormal cancer screening test. Cancer Epidemiol Biomarkers Prev; 21(10); 1620-8. (c) 2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据